Combination of a Serotonin Reuptake Inhibitor and Amoxapine
AssigneeH. Lundbeck A/S
InventorsThomas Ivo Cremers, Sandra Willigers, Jorn Arnt
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of a combination of Amoxapine and a serotonin reuptake inhibitor (SRI), or any other compound, which causes an elevation in the level of extracellular serotonin, for the treatment of depression and other affective disorders.
Claims18
(canceled)
A method for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin, the method comprising administering a pharmaceutical composition comprising (a) Amoxapine or a pharmaceutically acceptable salt thereof, (b) a compound, which is a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin, and (c) optionally a pharmaceutically acceptable carrier or diluent to a patient in need thereof.
A pharmaceutical composition comprising Amoxapine or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin, and optionally pharmaceutically acceptable carriers or diluents.
A kit comprising Amoxapine or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin, and optionally pharmaceutically acceptable carriers or diluents.
Dependencies are inferred from the claim text.